Previous 10 | Next 10 |
2024-06-03 11:04:50 ET Summary Today, we look at Natera, Inc., a diagnostic and molecular testing services company that has seen its stock rise over 150% since late October. The company achieved cash flow break even status in the first quarter ahead of schedule as Natura delivered...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 7:40 a.m. PT (10:40 a.m. ET). A live webcast may be accessed through the investor...
2024-06-02 23:01:06 ET Summary Duquesne Family Office's 13F portfolio value increased from $3.35B to $4.39B in Q1 2024. The largest five stakes in the portfolio are Microsoft, Coupang, Teck Resources, Vistra Corp., and Natera, Inc. Stanley Druckenmiller's family office made ne...
Includes new results from the ProActive study, reinforcing the utility of the Prospera™ Kidney test for ongoing surveillance of transplant rejection Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that the company wil...
2024-05-26 10:15:00 ET Summary Parnassus Investments is a fundamental, bottoms-up investment firm offering responsible investment funds to the public. Parnassus Investments integrates comprehensive ESG evaluations with fundamental financial analysis to select investments. The Fund...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that members of Natera’s management will present at the 2024 Leerink Partners Healthcare Crossroads Conference on Thursday, May 30, 2024 at 8:40 a.m. PT (11:40 a.m. ET). A live webcast ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the company, along with its collaborators, will present new data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4, 2024. The pre...
2024-05-15 16:27:14 ET Read the full article on Seeking Alpha For further details see: Duquesne Family Office top Q1 buys, cuts: Coherent, Eli Lilly, others
2024-05-13 08:30:06 ET BTIG analyst issues BUY recommendation for NTRA on May 13, 2024 07:22AM ET. The previous analyst recommendation was Buy. NTRA was trading at $105.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst re...
A look at the top 10 most actives in the United States Novavax Inc. (NVAX) rose 98.7% to $8.88 on volume of 168,692,127 shares AEye Inc. (LIDR) rose 115.0% to $2.58 on volume of 156,236,079 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) fell 17.3% to $0.7609 on volume of 123,678,040 s...
News, Short Squeeze, Breakout and More Instantly...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2024, after the market close on Aug. 8, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...